Cocaine Use Disorder (CUD) is characterized as a substance use disorder in which biological, psychological, and genetic characteristics are supposed to predispose an individual to addiction. Cocaine causes the brain to release large amounts of a chemical called dopamine. This chemical activated the reward center of the brain. Over time, more cocaine is needed to cause the same release of chemicals, leading to misuse.
Currently, no drug is approved to treat cocaine addiction; however, psychosocial treatment is the standard treatment for addicted patients. The social stigma revolving around Cocaine Use Disorder and lack of awareness about the misuse obstructs the creation of standard CUD treatment options. Explore more about the Cocaine Use Disorder Newsletter condition, its causes, signs and symptoms, epidemiological insights, and currently available therapeutic options through DelveInsight’s Newsletter. It also includes the recent news in the Cocaine Use Disorder market, its pipeline therapies, ongoing clinical trials, key pharmaceutical companies working in the CUD domain. Gain rich insights into significant collaborations, licensing opportunities, and conferences that are taking place in the Cocaine Use Disorder field. Are you curious about what the coming years hold for the Cocaine Use Disorder market and how pharma companies are working to push the drug development? Download our Newsletter by simply filling up the form towards the right. Subscribe to our mailing list and stay informed about all the fresh updates in the Substance Use Disorder market. Know More About What's Covered: · Indication overview · Signs, symptoms, and diagnosis · Epidemiological trends · Treatment approaches · R&D in the field · Top conferences · News flash · Recent Research Activities · Support from International organizations · Market insights · Cocaine Use Disorder Market Dynamics · Collaborations and deals in the domain Download Cocaine Use Disorder Newsletter - https://www.delveinsight.com/whitepaper-newsletter/cocaine-use-disorder-market #raredisease #rare #disease #medicalsciences #newsletter #promotion #covid19 #healthcare #business #cocaineusedisordernewsletter #cocaineusedisorder #readerscommunity #readinglist #newsletterdesign You may read our latest reports-
DelveInsight’s SGLT2 inhibitors Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the SGLT2 inhibitors, historical and forecasted epidemiology as well as the SGLT2 inhibitors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The SGLT2 inhibitors market report provides current treatment practices, emerging drugs, SGLT2 inhibitors market share of the individual therapies, current and forecasted SGLT2 inhibitors market Size from 2018 to 2030 segmented by seven major markets. The Report also covers current SGLT2 inhibitors treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. What are the SGLT2 Inhibitors regions? The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan. What is SGLT2 Inhibitors Market Share? The DelveInsight SGLT2 inhibitors market report gives a thorough understanding of the SGLT2 inhibitors by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. This segment of the report covers the detailed diagnostic methods or tests for SGLT2 inhibitors. It covers the details of conventional and current medical therapies available in the SGLT2 inhibitors market for the treatment of the condition. It also provides SGLT2 inhibitors treatment algorithms and guidelines in the United States, Europe, and Japan. What is SGLT2 Market Drug? Drug chapter segment of the SGLT2 inhibitors report encloses the detailed analysis of SGLT2 inhibitors marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the SGLT2 inhibitors clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The report provides the details of the marketed product available for SGLT2 inhibitors treatment. The report provides the details of the emerging therapies under the late and mid-stage of development for SGLT2 inhibitors treatment. What is SGLTS Inhibitors Market Size? The SGLT2 inhibitors market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted SGLT2 inhibitors market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a thorough detail of SGLT2 inhibitors market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. This section includes a glimpse of the SGLT2 inhibitors market in 7MM. This section provides the total SGLT2 inhibitors market size and market size by therapies in the United States. The total SGLT2 inhibitors market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section. What is SGLT2 Market Drugs Uptake? This section focusses on the rate of uptake of the potential drugs recently launched in the SGLT2 inhibitors market or expected to get launched in the market during the study period 2018-2030. The analysis covers SGLT2 inhibitors market uptake by drugs; patient uptake by therapies; and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. To keep up with current market trends, we take KOLs and SME’s opinion working in SGLT2 inhibitors domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or SGLT2 inhibitors market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs. We perform Competitive and Market Intelligence analysis of the SGLT2 inhibitors Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability. Lupus Nephritis (LN) is one of the most common manifestations of systemic lupus erythematosus (SLE), affecting approximately 40% of patients with lupus. It constitutes a significant risk factor for morbidity and mortality, and it is also anticipated that 10% of patients with Lupus Nephritiswill develop end-stage kidney disease (ESKD).
DelveInsight estimates a robust Lupus Nephritis pipeline with more than 20 drugs under different phases of clinical development. Although there is a presence of many therapeutic drugs for the Lupus Nephritis treatment domain, there is still no permanent cure found for the condition. DelveInsight offers a brand new inclusion to its newsletter edition that pivots on the Lupus Nephritis domain. The newsletter encompasses the Lupus Nephritis treatment landscape constituting the current, marketed and upcoming, novel drugs in the LN therapeutic area. Also, details of the Lupus Nephritis market, epidemiological insights, ongoing clinical trials, pipeline therapies are expected to transform the LN market in the coming decade are all covered. Dive deep into rich insights of Lupus Nephritis latest news and happenings, mergers and collaborations, critical pharmaceuticals involved, licensing deals along with events and grand conferences taking place in the Lupus Nephritis market space. Subscribe to our mailing list and stay informed about all the latest developments in the Autoimmune Diseases therapeutic market. Download our Lupus Nephritis Newsletter by simply filling up the form towards the right and stay in touch to learn more about our fresh offerings and services. Know More About What's Covered:
Download Lupus Nephritis Newsletter- https://www.delveinsight.com/whitepaper-newsletter/lupus-nephritis-newsletter #raredisease #rare #disease #medicalsciences #newsletter #promotion #covid19 #healthcare #business #lupusnephritisnewsletter #lupusnephritis #readerscommunity #readinglist #newsletterdesign Some of the highlighted reports given here- · Biotech Consulting · Medical Marijuana Market · Ranibizumab Biosimilar Insight · ARDS Market · Technical Due Diligence Firms · Respiratory Syncytial Virus Infections Market Neuromyelitis Optica Spectrum Disorder NewsletterNeuromyelitis Optica Spectrum Disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord which causes inflammation in the optic nerve and spinal cord. Currently, the Neuromyelitis Optica Spectrum Disorder domain constitutes a robust pipeline with more than 20 drugs existing in the NMOSD therapeutic landscape, out of which 3 are marketed, and 17 are under different phases of development. DelveInsight presents a new addition to its newsletter edition that focuses on the Neuromyelitis Optica Spectrum Disorder market. The newsletter offers a complete picture of the Neuromyelitis Optica Spectrum Disorder market landscape, pipeline therapies, ongoing clinical trials, as well as epidemiological insights, and current treatment therapies. It also covers recent happenings in the Neuromyelitis Optica Spectrum Disorder market space, mergers and collaborations taking place, research & development, essential pharmaceutical companies involved in the Neuromyelitis Optica Spectrum Disorder market, licensing deals along with the details of top conferences expected to occur in the coming year. Download our Neuromyelitis Optica Spectrum Disorder Newsletter by filling up the form towards the right and stay informed about recent updates in the Neuromyelitis Optica Spectrum Disorder market. Join our Newsletter series and get rich insights delivered every week to you. Stay connected! Know More About What's Covered: · Indication overview · Signs, symptoms, and diagnosis · Epidemiological trends · Treatment approaches · Unmet needs · Top conferences · R&D in the field · News Flash · Recent Research Activities · Support from International organizations · Market insights · Neuromyelitis Optica Spectrum Disorder Market Dynamics · Collaborations and deals in the domain Download Neuromyelitis Optica Spectrum Disorder Newsletter- https://www.delveinsight.com/whitepaper-newsletter/neuromyelitis-optica-spectrum-disorder-market #raredisease #rare #disease #medicalsciences #newsletter #promotion #covid19 #healthcare #business #alopeciaareata #neuromyelitisopticaspectrumdisordernewsletter #readerscommunity #readinglist #newsletterdesign Some of the highlighted reports given here- · Biotech Consulting · Medical Marijuana Market · Ranibizumab Biosimilar Insight · ARDS Market · Technical Due Diligence Firms · Respiratory Syncytial Virus Infections Market Virtual clinical trials (VCTs) are site-less clinical trials, which utilizes technology along with the inclusion of web platforms for recruitment, counseling, measurement of endpoints, adverse reaction study, and many such procedures that are followed during a traditional clinical trial; allowing the patients to be home-based at every stage of the clinical trial.
VCTs are cost-effective, faster, with better retention rates, have good demographic representation and, are time-saving trials. There are few limitations associated with virtual trials such as it is restricted for life-threatening diseases or one that require large procedures such as biopsies, high imaging systems capital equipment such as MRI cannot be performed as virtual trials. Through this whitepaper, DelveInsight is representing the current scenario of virtual clinical trial in the pharmaceutical and medical device industry. The whitepaper includes an overview, comparison between traditional and virtual clinical trial, impact of COVID-19 on clinical trial, past and on-going virtual clinical trial, major services provider, and conclusion. The virtual clinical trials are helping companies and patients to conduct clinical trial without visiting the site, reducing the cost, monitor their vitals independently and remotely, thus, having better retention rate. The key providers of VCTs solutions are Obvio Health USA, Inc., CLINPAL, VIRTRIAL, Lightship, Medable, Science 37, Parexel International Corporation, Medidata, PRA Health, and Curavit Clinical Research, among others. Virtual Clinical Trials Whitepaper has made it easier to conduct clinical trials in the time of pandemic when patients can't travel to clinical trial locations due to restrictions in movement to curb the virus spread. It will bring in a new future of remote accessibility, affordability, and more flexible implementation of clinical studies by taking the clinical trial research on the patients' doorstep. Download whitepaper- https://www.delveinsight.com/whitepaper-newsletter/virtual-clinical-trials #healthcare #digitalhealth #healthtech #medtech #clinicaltrials #medicaldevices #research #biotech #data #health #opportunities #pharmaceuticalindustry #diagnostics #cancer #medicine #work # virtualclinicaltrials #virtualclinicaltrials Well, Myelodysplastic Syndrome is one of the rare blood cancers, has been in the limelight of researchers for a decade as it is not merely cancer, indeed, needs their utmost attention towards the curative treatment before the patients succumb to this deadly disease.
Fortunately, the beginning of the 21st century has seen a lot coming out from the research such as approvals of hypomethylating agents, immunomodulatory agent’s erythroid maturation agents, and others were blood transfusions, erythropoietin-stimulating agents (ESAs), recombinant human granulocyte colony-stimulating factor (G-CSF) or GM-CSF were considered to be the only options for the disease; even in relapsed cases. Through the Myelodysplastic Syndrome whitepaper, Delveinsight will draw your attention towards the evolution history of the disease, from the disease classification in the past to the paradigm shift in the current treatment. This paper also highlights how several emerging therapies in the pipeline might impact the current treatment regimens, cost analysis of recently approved therapies, special emphasis on therapies with breakthrough designations, insights on the revised prognostic system along a discussion on Myelodysplastic Syndrome types. In addition, the paper also underlines the various clinical unmet needs in the area which remain unaddressed till today. Through this Myelodysplastic Syndrome whitepaper, the reader can get an overview of the future developments in the universe of MDS therapies. Know More About What's Covered: · Sneak peek into the past · Why is MDS known as a Syndrome? · Revision of Prognostic Scoring System · Active players involved · Emerging therapies deep diving · Potential Emerging players targeting mutations in MDS space · Change in Treatment Paradigm · Are these therapies pocket-friendly for patients · Estimated Revenue of Inqovi and Reblozyl · Summary table comprising of emerging therapies Download whitepaper here- https://www.delveinsight.com/whitepaper-newsletter/myelodysplastic-syndrome-mds-market-analysis #healthcare #digitalhealth #healthtech #medtech #clinicaltrials #medicaldevices #research #biotech #data #health #opportunities #pharmaceuticalindustry #diagnostics #cancer #medicine #work #weartechnolgoy #myelodysplasticsyndrome |
AuthorMickey Len |